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Background/Aims: Epithelial-to-mesenchymal transition (EMT) in cancers is related to metastasis, recurrence, and
poor prognosis. We evaluated whether EMT-related proteins can act as prognostic biomarkers in colorectal cancer
(CRC) patients.
Methods: We evaluated the expression of E-cadherin, β-catenin, and S100A4 by immunohistochemistry (IHC) in 333 CRC
tissues from the tumor center and invasive margin. Tumor budding, cell grade, tumor stage, type of tumor growth,
peritumoral lymphocyte infiltration (TLI), and perineural- or lymphovascular invasion were evaluated as pathological
parameters. mRNA levels of E-cadherin, N-cadherin, β-catenin, and S100A4 from 68 specimens from the same set were
analyzed by real time quantitative RT-PCR.
Results: Loss of E-cadherin, nuclear β-catenin, and gain of S100A4 were higher in the invasive margin than in the tumor
center. Loss of E-cadherin was associated with cell grade, macroscopic type, perineural invasion, and tumor budding,
β-catenin with microsatellite instability and tumor site, and S100A4 with growth type, macroscopic type, AJCC stage,
lymphovascular invasion, and perineural invasion. The aberrant expression of E-cadherin and S100A4 not β-catenin in
the invasive margin was a significant and independent risk factor for disease-free and overall-survival by multivariate
analysis, along with AJCC stage and perineural invasion. mRNA levels of β-catenin and S100A4 were correlated
with the IHC findings at the tumor invasive margin. E-cadherin and N-cadherin showed a weak inverse correlation.
Conclusions: The combination of loss of E-cadherin and gain of S100A4 in the tumor invasive margin can be used
to stratify patients with the same AJCC stage into different survival groups.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9398289629244673
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The incidence of colorectal cancers (CRC) has been in-
creasing in Korea since 1999. In 2009, CRC was the fourth
most fatal cancer [1]. Although the 5-year survival rate of
CRC overall has been reported to be as high as 71.3% [1],
the survival rate in patients with recurrence is only 40%* Correspondence: smpark@chungbuk.ac.kr
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reproduction in any medium, provided the or[2]. The recurrence rate of stage I - III CRC patients who
received curative resection has been reported to be 27.3%
[2]. In addition to American Joint Committee on Cancer
(AJCC) stage, biomarkers to predict recurrence are needed
to select those patients who should be treated more aggres-
sively. The growth pattern of the invasive margin, tumor
budding, tumor grade, perineural invasion, and lympho-
vascular invasion have been reported to predict a poor
prognosis [3,4]. Tumor buds are thought to be responsible
for the subsequent steps in invasion and metastasis [5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lial to mesenchymal transition (EMT) [6].
EMT is the process by which mature epithelial cells
change in appearance and lose cell–cell contacts and epi-
thelial protein expression while at the same time acquiring
the phenotypic characteristics of mesenchymal cells [7].
Many different EMT-related proteins and transcriptional
factors that promote tumor progression and local or dis-
tant metastasis have been reported. Immunohistochemical
staining (IHC) of human tissues obtained from patients
with CRC demonstrated that the loss or attenuation of
epithelial marker expression and the gain of mesenchymal
marker expression are closely related to tumor progres-
sion and poor prognosis.
The initial step in tumor invasion and metastasis is the
break-up of adhesion junctions mediated by E-cadherin,
resulting in extension of the tumor cells into the stroma
and their attachment to the extracellular matrix. Loss of
E-cadherin in CRC correlates with clinicopathologic fea-
tures of aggressive CRC and predicts poor prognosis [8].
Dysfunction of the Wnt-signaling pathway plays an im-
portant role in colorectal carcinogenesis and Wnt signaling
dysfunction leads to the nuclear accumulation of ß-catenin
[9]. Nuclear translocation of β-catenin triggers an EMT
and a proinvasive gene expression [10]. Nuclear β-catenin
expression has been observed in advanced CRC, but the
prognostic significance was not clarified; it was related to
poor prognosis [11], no effect [9,12] or even favorable
prognosis [13]. S100A4 is directly involved in the forma-
tion of metastasis from several different tumor types via
increased cell motility and invasion [14]. In CRC, nu-
clear expression of this protein is related to advanced
tumor stage [15] and poor metastasis-free and overall
survival [16]. EMT-related proteins such as E-cadherin,
β-catenin, and S100A4 are known to be related to carcino-
genesis and tumor progression, but the relation of these
protein expressions and whether these proteins can serve
as prognostic biomarkers of CRC were not clarified.
The aim in this study was to evaluate whether EMT-
related protein expression and clinicopathological features
of CRC are useful prognostic predictors or not. We com-
pared the patterns of EMT protein expression in the tumor
center and invasive margin and determined if there were
correlations between the IHC findings and mRNA expres-
sion levels of various EMT-related genes.
Methods
Patients and tissue samples
Paraffin-embedded tissues were obtained from the de-
partment of pathology and fresh frozen specimens were
provided by the National Biobank of Korea, with the
approval of the Ethics Committee of Chungbuk National
University Hospital. Three hundred thirty-three CRC pa-
tients (male:female, 189:144), who underwent completeresection (R0) and were followed-up for more than 5 years
were enrolled in this study. The patients did not receive
any chemotherapy or radiation therapy before surgery.
Among the enrolled patients, 68 fresh-frozen specimens
were obtained for real time RT-PCR. At the time of sur-
gery, tumor tissues and matched normal tissues were
immediately sampled from the resected colorectal speci-
men by pathologists. The tissue was frozen in liquid nitro-
gen, and kept at −80°C.
Histopathology
Each tumor was re-evaluated by analysis of the medical
records and the tissue slide files by one pathologist. Tumor
location (right side or left side), the degree of differentiation
(well, moderately, and poorly), depth of tumor invasion,
lymph node or distant metastasis, and microsatellite status
(characterized in 166 cases) were assessed. The stages were
defined according to the TNM staging system of AJCC. We
also reviewed macroscopic type (polypoid, ulcerofungating,
and ulceroinfiltrative), invasion to the lymphatics or vessels,
and perineural invasion. Tumor growth was classified as
expanding- or infiltrative-type and tumor budding was
evaluated by cytokeratin staining. The number of tumor
buds was counted in five regions of clusters of tumor cells
comprising less than 5 cells at 200x magnification. We
divided cases into those with low (median <10) or high
budding (median ≥ 10) (Figure 1).
Tissue microarray (TMA) construction and
immunohistochemistry (IHC)
After all slide reviews, 3-mm sized TMAs were constructed.
Areas from the center and the invasive margin of the tumor
with the lowest degree of differentiation but abundant in
cells with high mitotic activity were chosen from the ori-
ginal blocks. These representative areas were marked by an
experienced pathologist on hematoxylin and eosin (H&E)-
stained slides from selected paraffin blocks. Serial 4-um
sections were then cut from the TMA paraffin blocks.
The sections were mounted on Capillary Gap plus Slides.
Before IHC staining, all sections were deparaffinized and
heated in citrate buffer (10 mM/L citric acid, pH 6.0) in
a microwave oven. After inactivation by exposure to 3%
H2O2 for 10 min, the sections were incubated with blocking
serum at room temperature for 10 min. IHC staining
was carried out using anti-E-cadherin (DakoCytomation,
Glostrup, Denmark, 1:400), anti-cytokeratin (LeicaMicro
systems, Wetzlar, Germany, 1:300), anti-β-catenin (Dako
Cytomation, Glostrup, Denmark, 1:400) and anti-S100A4
(DakoCytomation, Glostrup, Denmark, 1:800) as primary
antibodies. After incubation with secondary antibodies,
the expression of these markers in cells was detected
with diaminobenzidine (DAB; Sigma, St. Louis, MO, USA)
by enhancement with a SABC kit (ZSGB-BIO, Beijing,
China). Tissue sections stained without primary antibody
Figure 1 Representative pathologic features of colorectal cancer. Lymphovascular invasion (A), perineural invasion (B), lymphocyte infiltration
(mild, moderate, and severe) (C), and type of tumor growth (expanding D and infiltrative E). High tumor budding at the invasive margin stained with
hematoxylin and eosin (F) and cytokeratin expression (G).
Lee et al. Diagnostic Pathology 2013, 8:99 Page 3 of 10
http://www.diagnosticpathology.org/content/8/1/99served as a negative control. The slides were then coun-
terstained with hematoxylin. The results were assessed by
two pathologists who were blinded to the patients’ details.
E-cadherin immunostaining was evaluated according to a
method described previously [17]. E-cadherin staining was
classified as grade 0 (preserved) when more than 90% of
the CRC cells on a section showed strong membranous
staining, or grade 1 (reduced or lost) when less than 90%
of the CRC cells showed positive membranous staining.
For β-catenin, the percentage of tumor cells with nuclear
staining was evaluated and scored as grade 0 (0-30%) or
grade 1 (30-100%). To evaluate S100A4 expression, stain-
ing intensity was recorded as 0 (no staining), 1 (weak
staining), 2 (intermediate staining), or 3 (strong staining).
The proportion of stained cells was expressed as a per-
centage. The staining score was obtained by multiplying
the intensity and percentage of stained cells and classifiedas grade 0 (low expression) and grade 1 (high expression)
(Figure 2).
Real time quantitative RT-PCR of EMT related genes
Tumor and matched normal tissues were homogenized
and total RNA was isolated using an RNeasy Mini kit
(Qiagen, Tokyo, Japan) following the manufacturer’s in-
structions. All samples were treated with RNase-free DNase
(Qiagen). RNA quality control and quantification were car-
ried out on an Agilent 2100 Bioanalyzer using a RNA 6000
Pico LabChip (Agilent Technologies, Tokyo, Japan). First-
strand complementary DNA was made from total RNA
using the Prime Script RT-reagent kit (Amersham Biosci-
ences Europe GmbH, Freiburg, Germany) according to
the manufacturer’s instructions. To quantify the expres-
sion levels of E-cadherin, β-catenin, N-cadherin, and
S100A4, real-time PCR amplification was performed
Figure 2 Immunohistochemical staining for E-cadherin, β-catenin, and S100A4 in colorectal cancers (×400). E-cadherin, membranous
staining at the center of the tumor (A, arrow) and loss or attenuation of expression at the invasive margin of tumor buds (B, arrow). β-catenin,
membranous staining (C, arrow) and nuclear staining at the invasive margin of tumor buds (D, arrow). Negative (E, arrow) and positive (F, arrow)
staining for S100A4.
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Mortlake, Australia). Real-time PCR assays using SYBR
Premix EX Taq (TAKARA BIO INC., Otsu, Japan) were
carried out in micro-reaction tubes (Corbett Research,
Mortlake, Australia). The PCR reaction was performed
in a final volume of 10 μl, consisting of 5 μl of 2x SYBR
premix EX Taq buffer, 0.5 μl of each 5’- and 3’- primer
(10 pmol/μl), and 1 μl of sample cDNA. The product
was 10-fold serially diluted from 100 pg/μl to 0.1 pg/μl.
Dilution series of PCR products were used to establish
standard curves for real-time PCR. Spectral data were cap-
tured by using Rotor-Gene Real-Time Analysis Software
6.0 Build 14 (Corbett Research, Mortlake, Australia).
All samples were run in triplicate. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an






GAPDH TGAGAACGGGAAGCTTGTCAnormalized to the expression of GAPDH. Primers and
product sizes for E-cadherin, N-cadherin, β-catenin, S100A4,
and GAPDH are summarized in Table 1.Statistical analysis
Differences were compared using Fisher’s exact test or
Pearson’s test for qualitative variables and Student’s t-test
or analysis of variance for continuous variables. Prognosis
was determined by disease-free survival and overall sur-
vival. Prognostic factors were examined by univariate
and multivariate analyses (Cox proportional hazards model).
All statistical tests were two sided, and statistical signifi-
cance was accepted at the P < 0.05 level. All analyses were








Table 2 Clinical and pathological characteristics of 333
patients with colorectal cancers
Characteristics N (%)
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Clinicopathologic parameters related to EMT-related
protein expression
Clinicopathologic characteristics of the patients showed
in Table 2. The relation between clinicopathological pa-
rameters and aberrant expression of E-cadherin, β-catenin
and S100A4 in the invasive margin was observed. Loss of
E-cadherin was related with cell grade (p = 0.050), macro-
scopic type (p = 0.014), perineural invasion (p = 0.037) and
high tumor budding (p = 0.010). Nuclear β-catenin expres-
sion was higher in microsatellite stable (MSS) than micro-
satellite instable (MSI) tumors (p = 0.004) and left CRCs
than in right CRCs (p = 0.037). S100A4 expression was
increased in infiltrative growth (p = 0.017), macroscopic
type (p = 0.024), T-stage (p = 0.010), nodal stage (p = 0.002),
AJCC stage (p = 0.001), ratio of metastatic lymph nodes
(p = 0.019), lymphovascular invasion (p = 0.034), and peri-
neural invasion (p = 0.050). It was also related with TLI
(p = 0.001) (Table 3).
Relation of E-cadherin,β-catenin and S100A4 expression
The aberrant expression of EMT-related proteins was
higher in the invasive margin than in the tumor center;
loss of E-cadherin, 17.9% versus 31.8% (p < 0.0001), nuclear
expression of β-catenin, 10.6% versus 12.5% (p < 0.0001),
and gain of S100A4, 10.2% versus 15.5% (p < 0.0001),
respectively. Aberrant expression of each protein was
related to the others: S100A4 versus E-cadherin (r = 0.312,
p = 0.050), S100A4 versus β-catenin (r = 0.166, p = 0.004)
and E-cadherin versus β-catenin (r = 0.152, p = 0.009).
Prognostic factors of disease-free survival and overall survival
Disease-free survival was associated with AJCC stage (p <
0.0001, Figure 3A), tumor budding (p = 0.007, Figure 3B),
tumor growth type (p = 0.003, Figure 3C), and perineural
invasion (p = 0.004, Figure 3D). Aberrant expression of
the E-cadherin (p = 0.007, Figure 3E), S100A4 (p = 0.004,
Figure 3F), and combination of both proteins in the in-
vasive margin were related to disease free survival
(p = 0.005, Figure 3G), whereas β-catenin was inversely
related (p = 0.032, Figure 3H). Multivariate Cox analysis
showed that combination of E-cadherin and S100A4 ex-
pressions in the invasive margin and the AJCC stage are
independent risk factor for disease-free survival (Table 4).
Overall survival was associated with AJCC stage (p < 0.0001,
Figure 4A), tumor budding (p = 0.01, Figure 4B), tumor
growth type (p = 0.01, Figure 4C), perineural invasion
(p = 0.02, Figure 4D), and TLI (p = 0.005, Figure 4E). Ab-
errant expression of E-cadherin (p = 0.002, Figure 4F),
S100A4 (p = 0.003, Figure 4G), and combination of both
proteins in the invasive margin were associated with
overall survival time (p = 0.0002, Figure 4H), whereas
β-catenin was not. Cox regression analysis showed that
the combination of E-cadherin and S100A4 in the
Table 3 Relation between clinico-pathological parameters and immunohistochemistry of E-cadherin, β-cadherin, and
S100A4 at invasive margin in colorectal cancers (n = 305)













Preoperative CEA (ng/ml) 7.0 ± 22.5 6.5 ± 12.4 0.811 6.5 ± 19.8 8.4 ± 18.3 0.573 5.3 ± 13.1 12.5 ± 35.7 0.014
MSI status (n = 166) 0.167 0.004 0.386
MSI-H (n = 8) 3(37.2) 5(62.5) 8(100.0) 0(0.0) 7(87.5) 1(12.5)
MSI-L (n = 6) 3(50.0) 3(50.0) 4(66.7) 2(33.3) 5(83.3) 1(16.7)
MSS (n = 135) 91(67.4) 44(32.6) 107(81.1) 25(18.9) 107(80.5) 26(19.5)
Tumor Location 0.455 0.037 0.704
Right (n = 66) 48(72.7) 18(27.3) *6.5 ± 18.7 60(87.0) 9(13.0)
Left (n = 236) 158(66.9) 78(33.1) *12.2 ± 22.7 194(84.0) 37(16.0)
Tumor Budding 0.011 0.799 0.480
Low (<10) (n = 263) 188(70.9) 77(29.1) 230(87.1) 34(12.9) 224(85.2) 39(14.8)
High (≥ 10) (n = 40) 20(50.0) 20(50.0) 37(90.2) 4(9.8) 32(80.0) 8(20.0)
Macroscopic Tumor Type 0.616 0.909 0.038
Polypoid (n = 21) 17(77.3) 5(22.7) 18(85.7) 3(14.3) 21(100.0) 0(0.0)
Ulcerofungating (n = 160) 109(66.9) 54(33.1) 143(88.3) 19(11.7) 138(86.3) 22(13.8)
Ulceroinfiltrative (n = 122) 82(68.3) 38(31.7 106(86.9) 16(13.1) 97(79.5) 25(20.5)
Tumor Grade 0.735 0.817 0.577
Well (n = 73) 53(72.6) 20(27.4) 64(86.5) 10(13.5) 60(82.2) 13(17.8)
Moderate or Poor (n = 227) 151(66.5) 73(34.0) 196(87.5) 28(12.5) 191(85.3) 33(14.7)
Ratio of Metastatic Lymph Node 0.11 ± 0.19 0.13 ± 0.21 0.567 0.12 ± 0.20 0.09 ± 0.19 0.317 0.11 ± 0.19 0.18 ± 0.23 0.019
Nodal Stages 0.567 0.288 0.002
N0 (n = 178) 128(70.3) 54(29.7) 155(85.2) 27(14.8) 161(90.4) 17(9.6)
N1 (n = 77) 49(63.6) 28(36.4) 69(92.0) 6(8.0) 57(74.0) 20(26.0)
N2 (n = 48) 31(67.4) 15(32.6) 43(89.6) 5(10.4) 38(79.2) 10(20.8)
Depth of Invasion 0.513 1.000 0.010
T1, T2 (n = 50) 38(73.1) 14(26.9) 44(88.0) 6(12.0) 48(96.0) 2(4.0)
T3, T4 (n = 253) 170(67.2) 83(32.8) 223(87.5) 32(12.5) 208(82.2) 45(17.8)
AJCC stage 0.272 0.669 0.001
I (n = 39) 27(67.5) 13(32.5) 35(87.5) 5(12.5) 37(94.9) 2(5.1)
II (n = 133) 96(71.1) 39(28.9) 114(85.1) 20(14.9) 119(89.5) 14(10.5)
III (n = 110) 74(68.5) 34(31.5) 97(89.8) 11(10.2) 81(73.6) 29(26.4)
IV (n = 21) 11(50.0) 11(50.0) 21(91.3) 2(8.7) 19(90.5) 2(9.5)
Lymphovascular Invasion 0.891 0.341 0.050
Negative 150(68.5) 69(31.5) 195(88.6) 25(11.4) 189(87.1) 28(12.9)
Positive 57(67.1) 28(32.9) 72(84.7) 13(15.3) 66(77.6) 19(22.4)
Neural Invasion 0.037 0.507 0.050
Negative 196(69.8) 85(30.2) 248(87.9) 34(12.1) 240(85.7) 40(14.3)
Positive 11(47.8) 12(52.2) 19(82.6) 4(17.4) 15(68.2) 7(31.8)
Lymphocyte infiltration 0.325 0.821 < 0.0001
Mild 70(72.9) 26(27.1) 88(88.9) 11(11.1) 70(71.4) 28(28.6)
Moderate 108(67.1) 53(32.9) 138(86.3) 22(13.8) 144(89.4) 17(10.6)
Severe 26(60.5) 17(39.5) 36(87.8) 5(12.2) 38(95.0) 2(5.0)
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Table 3 Relation between clinico-pathological parameters and immunohistochemistry of E-cadherin, β-cadherin, and
S100A4 at invasive margin in colorectal cancers (n = 305) (Continued)
Type of Tumor Growth 0.159 1.000 0.044
Expanding 79(73.1) 29(26.9) 93(87.7) 13(12.3) 96(90.6) 10(9.4)
Infiltrative 125(65.1) 67(34.9) 168(87.0) 25(13.0) 156(81.3) 36(18.8)
Lymph Node Ratio, number of metastatic lymph nodes / number of harvested lymph nodes; CEA carcinoembryonic antigen serum level, *, percentage of
β-catenin nuclear expression at invasive margin.
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sion were independent risk factors of overall survival
time (Table 5).
Association between mRNA expression and IHC findings
Transcript levels of β-catenin and S100A4 were correlated
with IHC findings at the tumor invasive margin; β-catenin
(r = 0.369, p = 0.003) and S100A4 (r = 0.504, p < 0.0001).
However, there was no relation between the RT-PCR data
and the IHC findings for E-cadherin. E-cadherin and N-
cadherin showed a weak inverse relation without statisticalFigure 3 Analysis of disease free survival time according to histopathol
tumor budding (B), type of tumor growth (C), Perineural invasion (D), E-cadhe
S100A4 (G), and β-catenin expression (H).significance (r = -0.169, p = 0.084). mRNA levels of N-
cadherin were higher in recurrent or mortality cases
(p = 0.040 and p = 0.042, respectively).
Discussion
In this study, we demonstrated that the combination of
the loss of E-cadherin and gain of S100A4 in the invasive
margin of CRC is an independent prognostic factor of a
poorer outcome, along with AJCC stage and perineural
invasion. Nuclear expression of β-catenin was not related
to patient survival.ogic parameters and EMT related protein expression. AJCC stage (A),
rin expression (E), S100A4 expression (F), combination of E-cadherin and
Table 4 Cox regression analysis for disease free survival
time in colorectal cancers
Parameters P value Hazard Ratio 95% CI
*EMT, invasive front 0.026 1.60 1.01-2.43
Lymphovascular invasion 0.625 1.15 0.90-4.28
Perineural invasion 0.092 1.96 0.90-4.28
Lymphocyte infiltration 0.987 1.00 0.66-1.52
Tumor growth type 0.306 1.43 0.72-2.85
Tumor budding (≥10/x200HPF) 0.168 1.61 0.82-3.15
AJCC stage 0.000 3.03 2.03-4.52
*EMT included the expressions of E-cadherin and S100A4.
Table 5 Cox multivariate analysis for overall survival time
in colorectal cancers
Parameters P value Hazard Ratio 95% CI
*EMT, invasive front 0.036 1.54 1.03-2.31
Lymphovascular invasion 0.963 1.01 0.58-1.78
Perineural invasion 0.010 2.58 1.25-5.34
Lymphocyte infiltration 0.696 0.92 0.60-1.41
Tumor growth type 0.119 1.73 0.87-3.44
Tumor budding (≥10/x200HPF) 0.778 0.90 0.60-1.41
AJCC stage 0.001 1.84 1.26-2.68
*EMT included the expressions of E-cadherin and S100A4.
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hesion molecules undergo alterations. Down-regulation
of E-cadherin in CRC is associated with malignant fea-
tures. Loss of E-cadherin has been shown to be associated
with tumor budding [18] and lymph node metastasis in
CRC [19] and to predict disease recurrence and long-termFigure 4 Analysis of overall survival time according to histopathologi
tumor budding (B), type of tumor growth (C), Perineural invasion (D), Perit
S100A4 expression (G), and combination of E-cadherin and S100A4 (H).survival in CRC [8,20,21]. In this study, loss of E-cadherin
at the invasive margin of CRCs was associated with high
tumor budding, perineural invasion, and a poor prognosis.
S100A4 is localized in the nucleus, cytoplasm, and extra-
cellular space and has a wide range of biological functions
ranging from regulation of angiogenesis to cell survival,c parameters and EMT related protein expression. AJCC stage (A),
umoral lymphocytic infiltration (TLI) (E), E-cadherin expression (F),
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sion in the invasive margin was increased in infiltrative
tumors, those with a lymph node metastasis, advanced
AJCC stage, or lymphovascular- and perineural invasion,
which are all parameters representing tumor aggressive-
ness. We demonstrated that high expression of S100A4
is associated with recurrence and mortality. These re-
sults were consistent to the previous studies [15,22,23],
in which S100A4 is related to a poor prognosis. One
study reported that S100A4 is overexpressed in cell pop-
ulations enriched for stem-like cells, which is associated
with Wnt/APC/β-catenin signaling pathway and S100A4
worked as β-catenin/TCF target gene [24]. Inconsistently
other results, S100A4 was also related to lymphocyte
infiltration, which protects tumor progression and de-
stroys tumor budding. These findings were resulted from
that S100A4 expressing fibroblasts, monocytes, macro-
phages, T lymphocytes, neutrophilic granulocytes, or endo-
thelial cells may be misinterpreted as S100A4 expressing
cancer cells [14].
β-catenin plays to maintain cell-to-cell adhesion along
with E-cadherin. However, β-catenin also acts as a tran-
scription factor in the Wnt signal transduction pathway
and Wnt signaling dysfunction leads to the nuclear accu-
mulation of ß-catenin [9]. Several studies have reported
that nuclear ß-catenin expression in the invasive margin is
associated with high tumor budding and poor prognosis
[11], whereas other studies did not find such a relationship
[9,12,20]. In addition, recent study showed that aberrant
β-catenin expression was related to favorable prognosis
[13]. We did not find any association between β-catenin
expression and tumor budding or overall survival in our
patient cohort. These inconsistencies may result from dif-
ferent CRC subtypes, the existence of more than one type
of CRC in a study [25], or different evaluation methods
[3]. We showed that β-catenin nuclear expression was in-
creased in MSS tumors compared to MSI tumors and that
it was higher in left CRCs than right CRCs. These results
are consistent with those of a previous study [26], which
reported that MSI-high, CpG island methylator phenotype
(CIMP)-high, and BRAF mutations, which are characteris-
tics of right CRCs, showed an inverse association with
cytoplasmic and nuclear β-catenin expression. MSS and
MSI colorectal cancers are increasingly being recognized
as distinct entities with significantly different pathological
characteristics, behaviors, and prognoses [27]. MSI is asso-
ciated with significantly lower levels of nuclear ß-catenin
and impaired EMT than MSS [27]. In agreement with
these reports, we found that 44.4% of MSI-H cases versus
72.4% of MSS or MSI-L cases were tumor budding positive.
Aberrant expression of E-cadherin, β-catenin, and S100A4
showed parallel patterns each other. These results sug-
gested that overexpression of S100A4 inhibits E-cadherin
expression and β-catenin plays a role in driving S100A4-dependent EMT induction [14]. Although individual change
of E-cadherin and S100A4 was related to patients’ prognosis
in univariate survival analysis, multivariate Cox analysis re-
vealed that the combination of E-cadherin loss and S100A4
overexpression was the only prognostic factor in addition
to AJCC stage, which is still the most important prognostic
factor in CRC. These results highlight the fact that multi-
marker phenotypes rather than single protein are needed in
IHC biomarker investigations [3].
Because the tumor biology of the invasive margin is
different than that of the tumor center, the patterns of
EMT protein expression are expected to be different at
the two sites. In this study, EMT-related changes in the
expression of E-cadherin, β-catenin and S100A4 were more
severe in the invasive margin than in the tumor center
and EMT changes in the invasive margin, but not the
tumor center, had prognostic significance.
Tumor budding is a putative hallmark of CRC cell inva-
sion and has previously been shown to be associated with
various clinicopathological parameters, including lymph
node metastasis, vascular and lymphatic invasion, distant
metastasis, local recurrence, and poor outcomes [28]. In
this study, high tumor budding was associated with the ra-
tio of metastatic lymph nodes, type of tumor growth, and
perineural invasion (data not shown). It has also been
classified as an additional prognostic factor. However, our
results suggest that the combination of E-cadherin and
S100A4 expression at the invasive margin of CRC is su-
perior to tumor budding for predicting prognosis.
The mRNA levels of E-cadherin, β-catenin, and S100A4
were not found to be associated with histopathological
parameters or prognosis in this study. For β-catenin and
S100A4, mRNA levels reflected that of the encoded pro-
tein, but this was not the case for E-cadherin. However,
the switch in expression from E-cadherin to N-
cadherin and the higher expression of N-cadherin in
patients with a poor prognosis were demonstrated in this
study. Recent study also showed that N-cadherin was
highly expressed in type II papillary renal cell carcinomas
than type I cancers and type II cancers were related to
poor prognosis [29].
In conclusion, our results suggest that aberrant expres-
sion of E-cadherin and S100A4 in the invasive margin
was well related with clinicopathological parameters and
IHC of both proteins is useful marker to predict progno-
sis in CRC.
Abbreviations
AJCC: American Joint Committee on Cancer; CRC: Colorectal cancer;
EMT: Epithelial-to-mesenchymal transition; GAPDH: Glyceraldehyde-3-
phosphate dehydrogenase; IHC: Immunohistochemistry; H&E: Hematoxylin
and eosin; MSI: Microsatellite instability; MSS: Microsatellite stable;
TLI: Peritumoral lymphocyte infiltration; TMA: Tissue microarray.
Competing interests
The authors declare that they have no competing interests.
Lee et al. Diagnostic Pathology 2013, 8:99 Page 10 of 10
http://www.diagnosticpathology.org/content/8/1/99Authors’ contributions
S-JL contstructed the manuscript. SYC and RS carried out pathologic study.
W-JK checked mRNA levels. MJ constructed tissue microarray. T-GL, B-RS,
SMY, and SJY were responsible for clinical data. SMP designed and
constructed manuscript. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by a grant from the National R&D Program for
Cancer Control, Ministry of Health and Welfare, Republic of Korea (1120330).
Author details
1Department of Surgery, Chungbuk National University College of Medicine
and Medical Research Institute, Cheongju, Chungbuk 361-763, Republic of
Korea. 2Department of Pathology, Chungbuk National University College of
Medicine and Medical Research Institute, Cheongju, Republic of Korea.
3Department of Urology, Chungbuk National University College of Medicine
and Medical Research Institute, Cheongju, Republic of Korea. 4Department of
Internal Medicine, Chungbuk National University College of Medicine and
Medical Research Institute, Cheongju, Republic of Korea. 5Department of
Laboratory Medicine, Chungbuk National University College of Medicine and
Medical Research Institute, Cheongju, Republic of Korea.
Received: 20 February 2013 Accepted: 21 May 2013
Published: 19 June 2013
References
1. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, Lee JS: Cancer statistics
in Korea: incidence, mortality, survival, and prevalence in 2009.
Cancer Res Treat 2012, 44:11–24.
2. Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW, Wang JY:
Predictive factors of early relapse in UICC stage I-III colorectal cancer
patients after curative resection. J Surg Oncol 2009, 100:736–743.
3. Zlobec I, Lugli A: Prognostic and predictive factors in colorectal cancer.
J Clin Pathol 2008, 61:561–569.
4. Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S,
Vlajnic T, Frattini M, Lugli A: Tumor budding predicts response to
anti-EGFR therapies in metastatic colorectal cancer patients. World J
Gastroenterol 2010, 16:4823–4831.
5. Prall F: Tumour budding in colorectal carcinoma. Histopathology 2007,
50:151–162.
6. Zlobec I, Lugli A: Epithelial mesenchymal transition and tumor budding
in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget
2010, 1:651–661.
7. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its
implications for fibrosis. J Clin Invest 2003, 112:1776–1784.
8. Elzagheid A, Buhmeida A, Laato M, El-Faitori O, Syrjänen K, Collan Y,
Pyrhönen S: Loss of E-cadherin expression predicts disease recurrence
and shorter survival in colorectal carcinoma. APMIS 2012, 120:539–548.
9. Brabletz T, Jung A, Hermann K, Gu¨nther K, Hohenberger W, Kirchner T:
Nuclear overexpression of the oncoprotein b-catenin in colorectal
cancer is localized predominantly at the invasion front. Pathol Res Pract
1998, 194:701–704.
10. Sánchez-Tilló E, De Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A:
β-catenin/TCF4 complex induces the epithelial-to-mesenchymal
transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl
Acad Sci U S A 2011, 108:19204–19209.
11. Baldus SE, Mönig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K,
Schneider PM, Thiele J, Hölscher AH, Dienes HP: MUC1 and nuclear
ß-catenin are coexpressed at the invasion front of colorectal carcinomas
and are both correlated with tumor prognosis. Clin Cancer Res 2004,
10:2790–2796.
12. Horkko TT, Klintrup K, Makinen JM, Napankangas JB, Tuominen HJ, Makela J,
Karttunen TJ, Makinen MJ: Budding invasive margin and prognosis in
colorectal cancer-no direct association with beta-catenin expression.
Eur J Cancer 2006, 42:964–971.
13. Wangefjord S, Brändstedt J, Ericson Lindquist K, Nodin B, Jirström K,
Eberhard J: Associations of beta-catenin alterations and MSI screening
status with expression of key cell cycle regulating proteins and survival
from colorectal cancer. Diagn Pathol 2013, 8:10.
14. Boye K, Maelandsmo GM: S100A4 and metastasis: a small actor playing
many roles. Am J Pathol 2010, 176:528–535.15. Flatmark K, Pedersen KB, Nesland JM, Rasmussen K, Aamodt G, Mikalsen S-O,
Bjørnland K, Fodstad Ø, Mælandsmo GM: Nuclear localization of the
metastasis-related protein S100A4 correlates with tumour stage in
colorectal cancer. J Pathol 2003, 200:589–595.
16. Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, Von
Wasielewski R: Prognostic significance of calcium binding protein S100A4
in colorectal cancer. Gastroenterology 2002, 123:1478–1484.
17. Asayama Y, Taguchi Ki K, Aishima Si S, Nishi H, Masuda K, Tsuneyoshi M:
The mode of tumour progression in combined hepatocellular carcinoma
and cholangiocarcinoma: an immunohistochemical analysis of
E-cadherin, alpha-catenin and beta-catenin. Liver 2002, 22:43–50.
18. Zlobec I, Lugli A, Baker K, Roth S, Minoo P, Hayashi S, Terracciano L, Jass JR:
Role of APAF-1, and peritumoral lymphocytic infiltration in tumour
budding in colorectal cancer. J Pathol 2007, 212:260–268.
19. Karamitopoulou E, Zlobec I, Patsouris E, Peros G, Lugli A: Loss of E-cadherin
independently predicts the lymph node status in colorectal cancer.
Pathology 2011, 43:133–137.
20. Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO,
Specterman S, De Kier Joffé EB, Pallotta MG, Puricelli LI, Lastiri J: Prognostic
value of E-cadherin, beta-catenin, MMPs (7 and 9) and TIMPs (1 and 2)
in patients with colorectal carcinoma. J Surg Oncol 2006, 93:151–160.
21. Ngan CY, Yamamoto H, Seshimo I, Ezumi K, Terayama M, Hemmi H,
Takemasa I, Ikeda M, Sekimoto M, Monden M: A multivariate analysis of
adhesion molecules expression in assessment of colorectal cancer. J Surg
Oncol 2007, 95:652–662.
22. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K: Nuclear
S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer
2010, 46:2919–2925.
23. Kho PS, Jankova L, Fung CL, Chan C, Clarke C, Lin BP, Robertson G, Molloy
M, Chapuis PH, Bokey EL, Dent OF, Clarke S: Overexpression of protein
S100A4 is independently associated with overall survival in stage C
colonic cancer but only in cytoplasm at the advancing tumour front.
Int J Colorectal Dis 2012, 27:1409–1417.
24. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD,
Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH: The
metastasis-associated gene S100A4 is a novel target of beta-catenin/
T-cell factor signaling in colon cancer. Gastroenterology 2006,
131:1486–1500.
25. Iacopetta B: Aberrant DNA methylation: have we entered the era of more
than one type of colorectal cancer ? Am J Pathol 2003, 162:1043–1045.
26. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R,
Meyerhardt JA, Fuchs CS, Ogino S: Correlation of beta-catenin localization
with cyclooxygenase-2 expression and CpG island methylator
phenotype (CIMP) in colorectal cancer. Neoplasia 2007, 9:569–577.
27. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY,
Iafrate AJ, Zukerberg LR, Chung DC: Epithelial to mesenchymal transition
is impaired in colon cancer cells with microsatellite instability.
Gastroenterology 2010, 138:1406–1417.
28. Wang LM, Kevans D, Mulcahy H, O‘Sullivan J, Fennelly D, Hyland J,
O‘Donoghue D, Sheahan K: Tumor budding is a strong and reproducible
prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009,
33:134–141.
29. Ludwig BC, Bernhard H, Arne S, Heinz-Joachim R, Felix B: N-cadherin is
differentially expressed in histological subtypes of papillary renal cell
carcinoma. Diagn Pathol 2012, 7:95.
doi:10.1186/1746-1596-8-99
Cite this article as: Lee et al.: Combined aberrant expression of E-cadherin
and S100A4, but not β-catenin is associated with disease-free survival and
overall survival in colorectal cancer patients. Diagnostic Pathology 2013 8:99.
